JP2003089647A5 - - Google Patents

Info

Publication number

JP2003089647A5

JP2003089647A5 JP1999063718A JP6371899A JP2003089647A5 JP 2003089647 A5 JP2003089647 A5 JP 2003089647A5 JP 1999063718 A JP1999063718 A JP 1999063718A JP 6371899 A JP6371899 A JP 6371899A JP 2003089647 A5 JP2003089647 A5 JP 2003089647A5

Authority

JP

Japan

Prior art keywords

zinc

hyaluronic acid

complex

molecular weight

weight ratio

Prior art date

1999-03-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims 13
• 239000011701 zinc Substances 0.000 claims 10
• 229910052725 zinc Inorganic materials 0.000 claims 10
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 9
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 9
• 229920002674 hyaluronan Polymers 0.000 claims 9
• 229960003160 hyaluronic acid Drugs 0.000 claims 9
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 3
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 3
• 230000006378 damage Effects 0.000 claims 3
• 201000010099 disease Diseases 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 208000012659 Joint disease Diseases 0.000 claims 2
• 239000003112 inhibitor Substances 0.000 claims 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
• 201000008482 osteoarthritis Diseases 0.000 claims 2
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
• 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
• 102000004877 Insulin Human genes 0.000 claims 1
• 108090001061 Insulin Proteins 0.000 claims 1
• 206010027476 Metastases Diseases 0.000 claims 1
• 206010003246 arthritis Diseases 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 230000009400 cancer invasion Effects 0.000 claims 1
• 230000001419 dependent effect Effects 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 229940125396 insulin Drugs 0.000 claims 1
• 230000009401 metastasis Effects 0.000 claims 1
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1